Objective: To examine whether a personalized chronic disease management approach induces a change in diabetes-related distress (DRD).
Methods: This pilot analysis - embedded in a clinical pharmacy program delivering care via telehealth and home visits, the Pharm2Home Initiative - utilizes a prospective design, comparing outcomes between two time points. DRD is measured using the Problem Areas in Diabetes 5-Item Scale (PAID-5). Inferential statistics were used to detect whether differences existed in each pair of PAID-5 item data and the total score.
Results: The primary and secondary outcomes are summarized below.
Conclusion: This preliminary analysis detected a significant difference in the total PAID-5 score with a 35% reduction from baseline, suggesting the personalized chronic disease management approach positively impacts participants’ DRD. Also, with no significant difference being detected in all measures within the secondary outcome, this intervention potentially induces a legacy effect where participants at least maintained a similar level of DRD three months after the intervention period. The outcomes thus far reflect an interprofessional effort, partnering clinical pharmacists with diabetologists and primary care providers to co-manage chronic diseases. Continuous monitoring is warranted to determine the program's impact on DRD.
K. Benowitz: None. S. Wong: None. C.F. Young: Other Relationship; Abbott.
